We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
+2.11%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$66.4M
AUM Growth
+$8.29M
(+14%)
Cap. Flow
+$122M
Cap. Flow
% of AUM
183.83%
Top 10 Holdings %
Top 10 Hldgs %
32.21%
Holding
297
New
108
Increased
49
Reduced
51
Closed
72
Top Buys
| 1 |
Incyte
INCY
|
+$3.53M |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$2.94M |
| 3 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$2.18M |
| 4 |
ARAV
Aravive, Inc. Common Stock
ARAV
|
+$1.54M |
| 5 |
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
|
+$1.37M |
Top Sells
| 1 |
General Mills
GIS
|
+$2.52M |
| 2 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$2.31M |
| 3 |
Amgen
AMGN
|
+$2.08M |
| 4 |
Abbott
ABT
|
+$1.72M |
| 5 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$1.56M |
Sector Composition
| 1 | Healthcare | 41.81% |
| 2 | Consumer Discretionary | 7.1% |
| 3 | Consumer Staples | 6.25% |
| 4 | Communication Services | 0.99% |
| 5 | Materials | 0.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
AB InBev
BUD
$156B
| $847K | 1.28% |
7,100
-109
| -2% | -$12.8K |
|
|
27
Abbott
ABT
$175B
| $843K | 1.27% |
15,800
-34,270
| -68% | -$1.72M |
|
|
DVAX
28
CALL
DELISTED
Dynavax Technologies
DVAX
| $796K | 1.2% |
50,700
-19,000
| -27% | -$301K |
|
|
DBVT
29
DBV Technologies
DBVT
$870M
| $786K | 1.18% |
+1,852
| New | +$794K |
|
|
SIOX
30
PUT
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $782K | 1.18% |
34,263
+30,563
| +826% | +$5.16M |
|
31
Mondelez International
MDLZ
$78.3B
| $720K | 1.09% |
17,700
-15,654
| -47% | -$665K |
|
|
32
PUT
Incyte
INCY
$23.4B
| $716K | 1.08% |
48,200
+34,200
| +244% | +$4.33M |
|
|
ARAV
33
PUT
DELISTED
Aravive, Inc. Common Stock
ARAV
| $694K | 1.05% |
+15,233
| New | +$1.54M |
|
|
TWX
34
DELISTED
Time Warner Inc
TWX
| $660K | 0.99% |
6,445
+3,995
| +163% | +$405K |
|
|
OTIC
35
PUT
DELISTED
Otonomy, Inc.
OTIC
| $645K | 0.97% |
94,800
+38,500
| +68% | +$519K |
|
|
FOLD
36
CALL
DELISTED
Amicus Therapeutics
FOLD
| $633K | 0.95% |
115,300
+31,000
| +37% | +$410K |
|
37
SCYNEXIS
SCYX
$42.4M
| $581K | 0.88% |
3,015
| – | – |
|
|
AIMT
38
DELISTED
Aimmune Therapeutics
AIMT
| $573K | 0.86% |
+23,100
| New | +$498K |
|
39
Sarepta Therapeutics
SRPT
$1.82B
| $568K | 0.86% |
12,522
-3,471
| -22% | -$139K |
|
40
DaVita
DVA
$15.2B
| $564K | 0.85% |
9,500
-5,139
| -35% | -$309K |
|
41
Insmed
INSM
$23.5B
| $560K | 0.84% |
17,953
-5
| -0% | -$95 |
|
42
Regeneron Pharmaceuticals
REGN
$70.9B
| $559K | 0.84% |
1,250
+591
| +90% | +$281K |
|
|
43
PUT
Teva Pharmaceuticals
TEVA
$37.3B
| $518K | 0.78% |
+229,100
| New | +$5.15M |
|
|
SIOX
44
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $514K | 0.77% |
9,334
+8,108
| +661% | +$1.37M |
|
45
Restaurant Brands International
QSR
$26B
| $505K | 0.76% |
+7,900
| New | +$488K |
|
46
AbbVie
ABBV
$450B
| $480K | 0.72% |
+5,403
| New | +$411K |
|
|
CASC
47
DELISTED
Cascadian Therapeutics, Inc.
CASC
| $471K | 0.71% |
115,206
-12,223
| -10% | -$46.8K |
|
|
ESPR
48
DELISTED
Esperion Therapeutics
ESPR
| $442K | 0.67% |
+8,825
| New | +$426K |
|
|
ZGNX
49
CALL
DELISTED
Zogenix, Inc.
ZGNX
| $396K | 0.6% |
+44,500
| New | +$604K |
|
50
Walmart Inc
WMT
$909B
| $391K | 0.59% |
+15,000
| New | +$394K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q3 2017 Portfolio in Review
As of Q3 2017, FT Options held 297 positions worth $66.4M, up 14% from $58.1M the previous quarter. Its ten largest holdings account for 32% of the portfolio.
FT Options deployed $122M of net new capital in Q3 2017, opening 108 new positions and adding to 49 existing holdings. Its largest new stake was Incyte: 27,887 shares worth $3.26M.
By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 38% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.
On the sell side, the largest reduction was General Mills, an estimated $2.52M trimmed.
- FT Options's largest Q3 2017 buy was Incyte: 27,887 shares worth $3.26M.
- FT Options added most to Sio Gene Therapies Inc. Common Stock in Q3 2017, an estimated $1.37M increase.
- FT Options's biggest Q3 2017 reduction was General Mills, cutting an estimated $2.52M.
- FT Options fully exited Portola Pharmaceuticals, Inc. in Q3 2017, selling an estimated $2.31M.
- FT Options's ten largest holdings make up 32% of its $66.4M portfolio in Q3 2017.
- FT Options opened 108 new positions and closed 72 in Q3 2017.
- FT Options's portfolio value rose 14% quarter-over-quarter to $66.4M.
Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.